Cloned (Comment) | Organism |
---|---|
expression of wild-type and mutant enzymes in Escherichia coli strain BL21(DE3) | Plasmodium vivax |
Crystallization (Comment) | Organism |
---|---|
apo-enzyme PvFKBD35 free and in complex with the tetrapeptide substrate succinyl-Ala-Leu-Pro-Phe-p-nitroanilide, sitting-drop vapor diffusion method, mixing of 0.0002 ml of 10 mg/ml protein in 10 mM phosphate, pH 6.8, 137 mM NaCl, and 2.7 mM KCl, with 0.0002 ml of precipitant solution containing 0.1 M Tris-HCl, pH 8.5, 30% w/v PEG 4000, 0.2 M MgCl2, and and equilibration against 0.1 ml precipitant solution, 18°C, X-ray diffraction structure determination and analysis at 1.4 A and 1.65 A resolution, respectively | Plasmodium vivax |
Protein Variants | Comment | Organism |
---|---|---|
Y100A | site-directed mutagenesis, the mutant shows about 10% reduced activity compared to the wild-type enzyme | Plasmodium vivax |
Y100E | site-directed mutagenesis, the mutant shows about 70% reduced activity compared to the wild-type enzyme | Plasmodium vivax |
Y100F | site-directed mutagenesis, the mutant shows about 10% reduced activity compared to the wild-type enzyme | Plasmodium vivax |
Y100L | site-directed mutagenesis, the mutant shows about 70% reduced activity compared to the wild-type enzyme | Plasmodium vivax |
Y100P | site-directed mutagenesis, the mutant shows about 50% reduced activity compared to the wild-type enzyme | Plasmodium vivax |
Y100R | site-directed mutagenesis, the mutant shows about 40% reduced activity compared to the wild-type enzyme | Plasmodium vivax |
Y100W | site-directed mutagenesis, the mutant shows about 30% reduced activity compared to the wild-type enzyme | Plasmodium vivax |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
FK506 | an immunosuppressive drug | Plasmodium vivax | |
Rapamycin | an immunosuppressive drug | Plasmodium vivax |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Plasmodium vivax | A5K8X6 | - |
- |
Purification (Comment) | Organism |
---|---|
recombinant wild-type and mutant enzymes from Escherichia coli strain BL21(DE3) by nickel affinity chromatography and gel filtration to near homogeneity | Plasmodium vivax |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
additional information | PPIase proteins catalyze the cis-trans isomerization of the peptidylprolyl bond, molecular interaction between the isomerase and a peptide substrate, overview | Plasmodium vivax | ? | - |
? | |
succinyl-Ala-Leu-Pro(omega180)-Phe-4-nitroanilide | the substrate binds to PvFKBD35 in a cis conformation involving residues D55, H67, V73, and I74 | Plasmodium vivax | succinyl-Ala-Leu-Pro(omega0)-Phe-4-nitroanilide | - |
? |
Synonyms | Comment | Organism |
---|---|---|
FK506 binding protein 35 | - |
Plasmodium vivax |
Peptidylprolyl cis-trans isomerase | - |
Plasmodium vivax |
PvFKBP35 | - |
Plasmodium vivax |
General Information | Comment | Organism |
---|---|---|
additional information | Y100 is a key residue for the catalytic activity, catalytic mechanism of PvFKBP35-mediated cis-trans isomerization of substrate, overview | Plasmodium vivax |